Recent Finacing
Recent Raise
iRegene develops iPSC-derived off-the-shelf cell therapies—NouvNeu001 for Parkinson’s and NouvSight001 for retinal degeneration—using a chemically induced platform; NouvNeu001 completed Phase I and entered multicenter Phase II.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
